


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0746.2003-001		APPLICATION NO. 10/764,985	
 INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 16, 2005 (Use several sheets if necessary)		FIRST NAMED INVENTOR Masanori Terajima		FILING DATE January 26, 2004	
		EXAMINER Not Yet Assigned		CONFIRMATION NO. 6782	
				GROUP 1642	

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
BL	A1	2004/0132132 A1	07-08-2004	Sahin, U., <i>et al.</i>
	A2	6,962,790 B1	11-08-2005	Ennis, F.
	A3	6,627,407 B2	09-30-2003	Ennis, F.
	A4	5,882,650	03-16-1999	Ennis, F.
	A5	5,766,601	06-16-1998	Ennis, F.
	A6	5,674,502	10-07-1997	Ennis, F.
	A7	4,603,112	07-29-1986	Paoletti, <i>et al.</i>

FOREIGN PATENT DOCUMENTS

BL	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	B1	WO 02/068682 A2	09-06-2002	Sahin, Ugur	X
	B2	EP 1 398 380 A1	03-17-2004	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	
	B3	WO 2004/024756 A2	03-25-2004	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	
	B4	WO 2004/067032 A2	08-12-2004	University of Massachusetts Medical Center	
	B5	WO 95/24925	09-21-1995	The Council of the Queensland Institute of Medical Research; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; Biotech Australia Pty. Limited; and CSL Limited	

EXAMINER /Bao Li/ (05/25/2006)	DATE CONSIDERED 05/25/2006
-----------------------------------	-------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 16, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0746.2003-001		APPLICATION NO. 10/764,985	
	FIRST NAMED INVENTOR Masanori Terajima		FILING DATE January 26, 2004	
	EXAMINER Not Yet Assigned		CONFIRMATION NO. 6782	GROUP 1642

FOREIGN PATENT DOCUMENTS						
BL		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
↓	B6	WO 97/45444	12-04-1997	The Council of the Queensland Institute of Medical Research; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; Biotech Australia Pty. Limited; and CSL Limited		
	B7	WO 99/02550	01-21-1999	The Council of the Queensland Institute of Medical Research; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; and CSL Limited		
	B8	WO 96/03144 A1	02-08-1996	The Council of the Queensland Institute of Medical Research; Commonwealth Scientific and Industrial Research Organisation; The University of Melbourne; The Walter and Eliza Hall Institute of Medical Research; Biotech Australia Pty. Limited; and CSL Limited		

EXAMINER /Bao Li/ (05/25/2006)	DATE CONSIDERED 05/25/2006
--	--------------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 16, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0746.2003-001		APPLICATION NO. 10/764,985	
	FIRST NAMED INVENTOR Masanori Terajima		FILING DATE January 26, 2004	
	EXAMINER Not Yet Assigned		CONFIRMATION NO. 6782	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BL	C1	Drexler, I., <i>et al.</i> , "Identification of Vaccinia Virus Epitope-Specific HLA-A*0201-Restricted T Cells and Comparative Analysis of Smallpox Vaccines," <i>Proc. Natl. Acad. Sci. USA</i> 100(1):217-222 (2003).
	C2	Terajima, M., <i>et al.</i> , "Quantitation of CD8 ⁺ T Cell Responses to Newly Identified HLA-A*0201-Restricted T Cell Epitopes Conserved Among Vaccinia and Variola (Smallpox) Viruses," <i>J. Exp. Med.</i> 197(7):927-932 (2003).
	C3	Ramirez, J.C., <i>et al.</i> , "Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison With the Western Reserve Strain and Advantages as a Vaccine," <i>J. Virol.</i> 74(2):923-933 (January 2000).
	C4	Gen Bank Acc. No. M35027 "Vaccinia Virus, Complete Genome," (1990, updated 2000).
	C5	Wagner, C., <i>et al.</i> , "Identification of an HLA-A*02 Restricted Immunogenic Peptide Derived from the Cancer Testis Antigen HOM-MEL-40/SSX2," <i>Cancer Immunity</i> 3:18 (2003).
	C6	Oseroff, C., <i>et al.</i> , "HLA Class I-restricted Responses to Vaccinia Recognize a Broad Array of Proteins Mainly Involved in Virulence and Viral Gene Regulation," <i>Proc. Natl. Acad. Sci. USA</i> 102(39):13980-13985 (2005).
	C7	Carroll, M.W., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: a Murine Tumor Model," <i>Vaccine</i> 15(4):387-394 (1997).
	C8	Carroll, M.W., and Moss, B., "Poxviruses as Expression Vectors," <i>Curr. Opin. Biotechnol.</i> 8(5):573-577 (1997).
	C9	DeLisi, C., <i>et al.</i> , "T-cell Antigenic Sites Tend to be Amphipathic Structures," <i>Proc. Natl. Acad. Sci. USA</i> 82:7048-7052 (1985).
	C10	Bixler, Jr., G.S., and Atassi, M.Z., "T Cell Recognition of Myoglobin: Localization of the Sites Stimulating T Cell Proliferative Responses by Synthetic Overlapping Peptides Encompassing the Entire Molecule," <i>J. Immunogenet.</i> 11(5-6):339-353 (1984).
✓	C11	Geysen, H.M., <i>et al.</i> , "The Delineation of Peptides Able to Mimic Assembled Epitopes," In <i>Synthetic Peptides as Antigens - Ciba Foundation Symposium 119</i> (Porter, R., and Whelan, J., Eds.), pp. 130-149, John Wiley & Sons, Chichester (1986).

EXAMINER /Bao Li/ (05/25/2006)	DATE CONSIDERED 05/25/2006
-----------------------------------	-------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 16, 2005 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0746.2003-001		APPLICATION NO. 10/764,985	
	FIRST NAMED INVENTOR Masanori Terajima		FILING DATE January 26, 2004	
	EXAMINER Not Yet Assigned		CONFIRMATION NO. 6782	GROUP 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BL	C12	Mathew, A., <i>et al.</i> , "Identification of Murine Poxvirus-Specific CD8 ⁺ CTL Epitopes with Distinct Functional Profiles," <i>J. Immunol.</i> 174:2212-2219 (2005).
BL	C13	Tscharke, D.C., <i>et al.</i> , "Identification of Poxvirus CD8 ⁺ T Cell Determinants to Enable Rational Design and Characterization of Smallpox Vaccines," <i>J. Exp. Med.</i> 201(1):95-104 (2005).
	C14	Gen Bank Acc. No. Y16780, "Variola Minor Virus Complete Genome," (2005), [online][retrieved on 11/14/2005].
	C15	Gen Bank Acc. No. X69198, "Variola Virus DNA Complete Genome," (2005), [online][retrieved on 11/14/2005].
	C16	Gen Bank Acc. No. L22579, "Variola Major Virus (Strain Bangladesh - 1975) Complete Genome," (1995), [online][retrieved on 11/14/2005].
	C17	Gen Bank Acc. No. AF095689, "Vaccinia Virus (Strain Tian Tan) Complete Genome," (2000), [online][retrieved on 11/14/2005].
	C18	Gen Bank Acc. No. M35027, "Vaccinia Virus, Complete Genome," (1993), [online][retrieved on 11/14/2005].
	C19	Gen Bank Acc. No. U94848, "Vaccinia Virus Strain Ankara, Complete Genomic Sequence," (2003), [online][retrieved on 11/14/2005].
	C20	Gen Bank Acc. No. AF482758, "Cowpox Virus Strain Brighton Red, Complete Genome," (2003), [online][retrieved on 11/14/2005].
	C21	Gen Bank Acc. No. AF380138, "Monkeypox Virus Strain Zaire-96-I-16, Complete Genome," (2001), [online][retrieved on 11/14/2005].
✓	C22	Bixler, G.S. and Atassi, M.Z., "Molecular Localization of the Full Profile of The Continuous Regions Recognized by Myoglobin Primed T-Cells Using Synthetic Overlapping Peptides Encompassing the Entire Molecule," <i>Immunological Communications</i> 12(6):593-603 (1983).

EXAMINER /Bao Li/ (05/25/2006)	DATE CONSIDERED 05/25/2006
-----------------------------------	-------------------------------